Journal of Immune Based Therapies and Vaccines

Table 3 HBsAg antibody responses

From: IMP321 (sLAG-3), an immunopotentiator for T cell responses against a HBsAg antigen in healthy adults: a single blind randomised controlled phase I study

Engerix^® -B				HBsAg + IMP321 10 μg
Subject	W0	W8	W12	Subject	W0	W8	W12
003	0	178	2253	013	0	0	1
008	0	2589	7055	015	0	0	4
014	0	0	54	017	0	0	0
023	0	4	442	018	0	2	28
026	0	3054	3156	019	9	504	609
032	0	0	28	020	0	0	0
040	0	9	164	1021	0	0	0
043	0	2	17	022	0	0	0
# Seroconverted^a	0	6 (75%)	8 (100%)	# Seroconverted^a	0	1 (14.2%)	3 (42.8%)
# Seroprotected^a	0	3 (37.5%)	8 (100%)	# Seroprotected^a	0	0	1 (14.2%)
GMT^{a, b}	1	23.75	313.56	GMT^{a, b}	1	1.10	1.96
HBsAg alone				HBsAg + IMP321 30 μg
006	0	0	0	025	0	0	0
012	0	0	0	027	0	0	0
016	0	0	0	029	0	0	0
024	0	0	0	030	0	0	26
028	0	0	7	031	0	0	0
034	0	0	0	033	0	0	4
039	0	0	2	035	2	136	467
044	1	24	321	036	0	0	0
# Seroconverted^a	0	0	2 (28.5%)	# Seroconverted^a	0	0	2 (28.5%)
# Seroprotected^a	0	0	0	# Seroprotected^a	0	0	1 (14.2%)
GMT^{a, b}	1	1	1.46	GMT^{a, b}	1	1	1.94
HBsAg + IMP321 3 μg				HBsAg + IMP321 100 μg
001	0	540	2229	037	0	0	3
002	0	35	51	038	0	0	3
004	0	0	0	041	0	0	0
005	0	0	0	042	0	0	0
007	0	0	1	045	0	0	0
009	0	0	12	046	0	0	0
1010	0	0	1	047	0	0	0
011	0	0	5	048	0	0	0
# Seroconverted^a	0	2 (25%)	6 (75%)	# Seroconverted^a	0	0	2 (25%)
# Seroprotected^a	0	2 (25%)	3 (37.5%)	# Seroprotected^a	0	0	0
GMT^{a, b}	1	3.42	7.15	GMT^{a, b}	1	1	1.31

Protective titres are indicated in bold
^a GMT, seroconversion and seroprotection calculations were based on naïve subjects only.
^b Value of zero are assigned the value of 1 for the GMT calculation.

Back to article page